FDA Approved: AFINITOR DISPERZ — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application to add Afinitor Disperz, the dispersible tablet form of everolimus, expanding formulation options for pediatric patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Angiomyolipoma
• Subependymal Giant Cell Astrocytoma
• Tuberous Sclerosis Complex

Drugs mentioned

• AFINITOR DISPERZ (everolimus)

Snippet

SUPPL AP for AFINITOR DISPERZ (EVEROLIMUS)